<DOC>
	<DOCNO>NCT01022190</DOCNO>
	<brief_summary>The purpose study determine whether Arcoxia effective preventing heterotopic ossification total hip arthroplasty .</brief_summary>
	<brief_title>Prevention Heterotopic Ossification With Arcoxia After Total Hip Replacement</brief_title>
	<detailed_description>Rationale : Heterotopic ossification frequent complication total hip replacement . Nonsteroidal anti-inflammatory drug ( NSAIDs ) know effectively prevent heterotopic ossification , gastrointestinal complaint report frequently . Selective cyclooxygenase-2 ( COX-2 ) inhibiting NSAID produce less gastrointestinal side effect . Objective : Preventing heterotopic ossification . Study design : A prospective two-stage study design phase-2 clinical trial 42 patient determine Arcoxia ( COX-2 inhibitor ) 90-mg oral prevents heterotopic ossification . In first stage , 19-patients include . Another 23-patients include least 90-percent patient first stage Brooker classification 0 , 1 2 6-months follow-up . Study population : 42-patients cement total hip arthroplasty age 18 - 75 yr old . Intervention : All subject receive 90-mg Arcoxia oral 7-days . Main study parameters/endpoints : The main study parameter degree heterotopic ossification assess AP radiograph use Brooker classification . Nature extent burden risk associate participation , benefit group relatedness : No risk associate participate research . Besides oral intake Arcoxia , extra burden associate participate study . The postoperative care change . Radiographic examination routinely perform day surgery , immediately operation , 6-weeks 6-months surgery . The degree heterotopic ossification determine x-ray assessment .</detailed_description>
	<mesh_term>Ossification , Heterotopic</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<criteria>Patients primary secondary hip osteoarthritis schedule cement total hip replacement Radboud University Nijmegen Medical Centre , Nijmegen , Netherlands . Written inform consent obtain patient legally accept representative . Patients rheumatoid arthritis , ankylose spondylitis , femoral neck fracture Patients previous allergic reaction nonsteroidal antiinflammatory drug Patients gastrointestinal complaint admission , history gastrointestinal ulcer perforation , inflammatory boweldisease , hepatic dysfunction , renal dysfunction clearance 30 ml/min cardiac insufficiency . Patients blood pressure consistently &gt; 140/90 mmHg adequately control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Arthroplasty</keyword>
	<keyword>Hip</keyword>
	<keyword>Cemented</keyword>
	<keyword>Heterotopic ossification</keyword>
	<keyword>Selective Cyclooxygenase-2 Inhibitors</keyword>
	<keyword>Arthroplasty , Replacement</keyword>
	<keyword>Hip Prosthesis</keyword>
	<keyword>Cyclooxygenase Inhibitors</keyword>
</DOC>